S

Sanofi

Global pharma company; vaccines and R&D

Talent Acquisition Partner

Full-TimeUpdated on 10/14/2026Deadline 10/30/26
No salary listed
Senior, Expert
Bachelor's
Taipei City, Taiwan
In Person
People & HRGeneralist Recruiting

About the job

Requirements
  • A bachelor's degree and 8–10 years of professional recruitment experience, or relevant transferable skills, are required; candidates should originally be from Taiwan, with other-market work experience such as mainland China preferred.
  • Experience in life sciences, pharma, or biotechnology industries within a multinational organization.
  • Proficiency in applicant tracking systems; Workday experience is a plus.
  • Expertise in recruiting methodologies, including sourcing, LinkedIn, job boards such as JobsDB and Taiwan104, and professional networking.
  • Experience in early-career recruitment, employer branding, and talent mapping.
  • Strong project management, business acumen, and stakeholder facilitation skills.
  • Fluency in spoken and written English and Mandarin Chinese; Cantonese proficiency is a plus.
Responsibilities
  • Collaborate with key regional stakeholders across Sanofi's three Global Business Units and functional leadership teams.
  • Partner with hiring managers to design, implement, and execute talent acquisition strategies aligned with the company's strategy and culture.
  • Lead the full recruitment lifecycle, from setting search strategies to executing metric-driven assignments.
  • Manage relationships with candidates, internal and external clients, recruitment process outsourcing partners, and vendors.
  • Generate a diverse pipeline of highly qualified candidates for Taiwan and Hong Kong.
  • Build and maintain strong university relations in the region.
  • Use innovative recruitment methods to deliver exceptional, diverse candidate pools.
  • Provide weekly, quarterly, and annual performance reports, including market feedback and insights.
  • Participate in industry events to amplify the company's presence in the marketplace.
  • Design and manage strategic recruitment projects related to diversity.
  • Ensure diverse candidate slates for each position.
  • Drive success in staffing metrics, including time to fill, diversity, source of hire, hiring manager satisfaction, recruitment compliance, and cost per hire.
  • Advise on candidate assessment, selection, and offer recommendations.
  • Identify recruitment challenges and provide timely solutions for both business-as-usual work and campaigns.
Desired Qualifications
  • Workday experience.
  • Cantonese proficiency.
  • Experience working in other markets, such as mainland China.
  • Experience with recruitment process outsourcing management and contingency or retained search firms.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)